🇺🇸 FDA
Pipeline program

GTX-102, GTX/UX Diluent and Flush Solution

GTX-102-CL210

Phase 2 small_molecule active

Quick answer

GTX-102, GTX/UX Diluent and Flush Solution for Angelman Syndrome is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Angelman Syndrome
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials